Dark

Check out our Level2View

NK
NantKwest, Inc. Common Stock
stock NASDAQ

Inactive

Mar 9, 2021

32.49USD+14.887%(+4.21)1,109,036

Pre-market

0.00USD-100.000%(-28.28)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Mar 10, 2021

09:06AM EST ImmunityBio Highlights Has Begun Trading On Nasdaq Following Merger With NantKwest, Trading On Ticker 'IBRX' Benzinga

Mar 9, 2021

04:15PM EST ImmunityBio and NantKwest Complete Merger Business Wire

Mar 8, 2021

04:30PM EST Stockholders of NantKwest Approve Merger With ImmunityBio Business Wire

04:30PM EST NantKwest, ImmunityBio Shareholders Approve Merger Deal Benzinga

09:01AM EST ImmunityBio And NantKwest Begin Dosing Participants In Global Trials For COVID-19 Vaccine Benzinga

09:00AM EST ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S. Business Wire

Feb 28, 2021

09:11AM EST Cramer Advises Viewers On First Solar, Madison Square Garden Sports And More Benzinga

Feb 26, 2021

03:00AM EST National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Infinity Q Diversified Alpha Fund, JELD-WEN Holding, Inc., and MiMedx Group, Inc. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966. GlobeNewswire Inc

Feb 24, 2021

07:26PM EST All Three Independent Proxy Advisory Firms - ISS, Glass Lewis and Egan-Jones - Recommend NantKwest Stockholders Vote "FOR" the Pending Merger With ImmunityBio Business Wire

09:00AM EST ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors Business Wire

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 20, 2021

05:35PM EST SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger Investigation GlobeNewswire Inc

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 17, 2021

10:40AM EST Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: GlobeNewswire Inc

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 16, 2021

09:43AM EST ImmunityBio Announces FDA Breakthrough Designation, Accelerated Approval For Co's Superagonist Anktiva N-803 Benzinga

09:42AM EST ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation Of Phase 2/3 Trial For BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS With 71% Complete Response Rate Benzinga

09:40AM EST NantKwest Announces Entered Into Agreement With ImmunityBio To Combine In A Stock-For-Stock Transaction Benzinga

09:11AM EST ImmunityBio Announces Presentation Of Phase 2/3 Trial Results Of BCG Unresponsive Non-Muscle Invasive Bladder Cancer RTTNews

09:00AM EST ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate Business Wire

Feb 13, 2021

12:06PM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, FFG, ALXN, NK, HLIX; PR Newswire

Feb 12, 2021

09:49AM EST Shares of NantKwest Inc. (NK) are rising over 7% Friday morning, following FDA clearance for the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce T-Cell, mucosal, and antibody immunity. RTTNews

05:25AM EST NantKwest/ImmunityBio's COVID-19 Vaccine Candidate To Be Tested For Oral And Sublingual Route Of Administration Benzinga

Feb 11, 2021

06:13PM EST ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity Business Wire

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 6, 2021

11:52AM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates NK, ALXN, CATM, CGIX, MTSC; PR Newswire

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 4, 2021

06:58PM EST National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Pluralsight, Inc., JELD-WEN Holding, Inc., and Applied Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966. GlobeNewswire Inc

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Feb 3, 2021

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Feb 2, 2021

04:54PM EST NANTKWEST INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of NantKwest, Inc. - NK Business Wire

10:37AM EST Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: GlobeNewswire Inc

Feb 1, 2021

07:02PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds NK, XLNX, GXGX, and ACEV Shareholders PR Newswire

Jan 30, 2021

06:04PM EST Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders PR Newswire

Jan 28, 2021

09:13AM EST ImmunityBio Reports Positive Phase 2 Results Showing That Anktiva Restores Activity Of Checkpoint Inhibitors In Patients RTTNews

09:06AM EST NantKwest Merger Partner ImmunityBio Announces Phase 2 Trial Results Showing 'Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer' Benzinga

09:00AM EST ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer Business Wire

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

08:00AM EST Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: GlobeNewswire Inc

Jan 25, 2021

03:37PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds PROS, IPHI, NK and XLNX Shareholders PR Newswire

Jan 21, 2021

05:09PM EST MERGER INVESTIGATION: Halper Sadeh LLP Investigates RP, BPFH, ALSK, NK, ANH; PR Newswire

04:24PM EST 'Excellent research from @Tuliodna et al. in South Africa about SARS-CoV-2 501Y.V2 variants. Antibodies block, but T cells kill. T-cell vaccines could play an important role in clearing the virus. #immunitybio' - Tweet From NantKwest Benzinga

02:17PM EST RM LAW Announces Investigation of NantKwest, Inc. PR Newswire

12:56PM EST INVESTIGATION ALERT: Nationally Ranked Shareholder Rights Law Firm Labaton Sucharow is Investigating NantKwest, Inc. (NASDAQ: NK) for Potential Securities Violations and Breach of Fiduciary Duty Business Wire

Jan 19, 2021

08:10AM EST NantKwest M&A Partner ImmunityBio Announces Phase I Trial Of COVID-19 Vaccine Candidate Benzinga

08:01AM EST Kaskela Law LLC announces that it is investigating NantKwest, Inc. (NantKwest) (NASDAQ: NK) on behalf of the companys shareholders. GlobeNewswire Inc

Jan 18, 2021

12:00AM EST Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: GlobeNewswire Inc

Jan 15, 2021

09:00PM EST SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the PR Newswire

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

04:43PM EST INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, PR Newswire

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

06:44AM EST NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars Benzinga

Jan 13, 2021

09:00PM EST SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of GlobeNewswire Inc

06:01PM EST NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials Business Wire

02:20AM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

Jan 12, 2021

07:11PM EST SHAREHOLDER ALERT: WeissLaw LLP Reminds WTRE, TNAV, RNET and NK Shareholders PR Newswire

Jan 7, 2021

04:18PM EST SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CHNG, BPFH, RP, MDCA, PR Newswire

Jan 6, 2021

09:00AM EST NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 Business Wire

Jan 5, 2021

11:18PM EST WeissLaw LLP Reminds RNET, NK, HMSY, and QEP Shareholders About Its Ongoing PR Newswire

05:36PM EST Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of NantKwest, Inc. (NASDAQ: NK) breached their fiduciary duties or violated the federal securities laws in connection with the companys merger with ImmunityBio, Inc. GlobeNewswire Inc

09:54AM EST Cramer Shares His Thoughts On AT&T, Nantkwest And More Benzinga

Dec 30, 2020

10:10AM EST Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GlobeNewswire Inc

Dec 29, 2020

08:58PM EST WeissLaw LLP Reminds RNET, NK, HMSY, and QEP Shareholders About Its Ongoing PR Newswire

06:40PM EST NANTKWEST INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of NantKwest, Inc. - NK Business Wire

Dec 28, 2020

08:20PM EST SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PR Newswire

11:22AM EST Kaskela Law LLC announces that it is investigating NantKwest, Inc. (NantKwest) (NASDAQ: NK) on behalf of the companys shareholders. GlobeNewswire Inc

08:07AM EST NANTKWEST (NK) SHAREHOLDER ALERT - Andrews & Springer LLC Is GlobeNewswire Inc

Dec 24, 2020

10:08AM EST NantKwest Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of NantKwest, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - NK Business Wire

Dec 23, 2020

05:59PM EST Rigrodsky & Long, P.A. announces that it is investigating NantKwest, Inc. (NantKwest) (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwests agreement to merge with ImmunityBio, Inc. GlobeNewswire Inc

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

10:02AM EST SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of GlobeNewswire Inc

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 21, 2020

07:56PM EST SHAREHOLDER ALERT: WeissLaw LLP Investigates NantKwest, Inc. PR Newswire

02:51PM EST Mid-Afternoon Market Update: Dow Turns Positive; uniQure Shares Slide Benzinga

12:13PM EST Mid-Day Market Update: Crude Oil Down 4%; 500.com Shares Spike Higher Benzinga

10:10AM EST Biopharma M&A Continues: Agios Sells Oncology Portfolio, NantKwest's Reverse Merger With ImmunityBio, Eyegate Picks Up Panoptes Benzinga

06:25AM EST ImmunityBio, a privately-held immunotherapy company, and therapeutics company NantKwest, Inc. (NK) announced Monday that they have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease. RTTNews

06:12AM EST ImmunityBio Announces Primary Endpoint Met Of Pivotal Phase 2/3 Trial RTTNews

06:08AM EST ImmunityBio And NantKwest Enter Agreement To Merge In Stock-for-stock Transaction RTTNews

06:08AM EST ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company Benzinga

06:07AM EST ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate Benzinga

06:05AM EST ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company Business Wire

06:05AM EST ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate Business Wire

Dec 10, 2020

11:06PM EST ImmunityBio's HAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection Of Airways In Non-Human Primates RTTNews

Nov 23, 2020

09:12AM EST ImmunityBio : Preclinical Data Shows IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing RTTNews

09:10AM EST ImmunityBio Announces Publication Of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing Benzinga

Nov 18, 2020

09:15AM EST NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference Business Wire

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

07:00AM EST ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study Business Wire

Nov 9, 2020

09:00AM EST ImmunityBio's hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2 Business Wire

Oct 27, 2020

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

Oct 26, 2020

04:15PM EDT NantKwest Names Richard Adcock Chief Executive Officer Business Wire

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 21, 2020

05:17PM EDT ImmunityBio And NantKwest Announce First Patient Dosed In Phase 1 Clinical Trial Of HAd5-COVID-19 RTTNews

05:06PM EDT ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2 Business Wire

05:03PM EDT ImmunityBio, NantKwest Reports First Patient Dosed In Phase 1 Trial Of Second-Generation COVID-19 Vaccine Candidate Benzinga

Oct 15, 2020

10:45AM EDT Shares of NantKwest, Inc. (NK) are rising more than 8% Thursday morning after the company said FDA has authorized ImmunityBio to start the phase I trial of its Covid-19 vaccine candidate, hAd5, which both the companies have been jointly developing. RTTNews

10:36AM EDT Why NantKwest's Stock Is Trading Higher Today Benzinga

06:58AM EDT NantKwest shares are trading higher after the company announced it has received authorization from the FDA to begin a Phase I clinical trial of hAd5-COVID-19, the company's COVID-19 vaccine candidate. Benzinga

06:14AM EDT ImmunityBio, Inc. has received authorization from the FDA to begin a phase I clinical trial of hAd5-COVID-19, the company's COVID-19 vaccine candidate. The company plans launching a phase I trial in the current month with adult subjects up to age 55. RTTNews

06:03AM EDT ImmunityBio: FDA Authorizes To Begin Phase I Clinical Trial Of HAd5-COVID-19 RTTNews

06:00AM EDT FDA Authorizes Phase 1 Trial of ImmunityBio's Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity Business Wire

05:47AM EDT NantKwest Announces FDA Authorizes Phase 1 Trial of ImmunityBio's Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity Benzinga

Oct 6, 2020

04:05PM EDT NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care Business Wire

Sep 21, 2020

09:00AM EDT NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit Business Wire

Sep 10, 2020

09:15AM EDT Brink Biologics Announces License Agreement With Fresenius Kabi SwissBioSim GmbH RTTNews

09:10AM EDT NantKwest Affiliate Brink Biologics Reports License Deal With Fresenius Kabi; Fresenius Has Joined List Of Companies Using Brink's NK-92 Cell Line For Bioanalytical Testing Benzinga

09:00AM EDT Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH Business Wire

Aug 24, 2020

09:05AM EDT NantKwest, ImmunityBio Sign Deal For Joint Development, Commercialization Of COVID-19 Vaccine And Related Therapeutics RTTNews

09:02AM EDT NantKwest And ImmunityBio Sign Collaboration Agreement For Joint Development, Manufacturing, Marketing, And Commercialization Of COVID-19 Vaccine And Related Therapeutics Benzinga

Aug 10, 2020

07:28AM EDT CBR By Generate Life Sciences And NantKwest To Develop COVID-19 Treatment Leveraging Newborn Stem Cells RTTNews

07:03AM EDT Cord Blood Registry By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment Benzinga

07:01AM EDT Cord Blood Registry (CBR(r)) By Generate Life Sciences Partners With NantKwest PR Newswire

Aug 3, 2020

08:36AM EDT ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins Benzinga

Jul 14, 2020

01:39PM EDT Natkwest Shares Move Higher; CEO Speaking On Fox Business Benzinga

Share